Optimal Strategy for Antiplatelet Therapy in Patients With Lower Extremity Artery Disease

Document Type : Original Article

Authors

Division of Cardiology, Department of Internal Medicine, Inje University Sanggye Paik Hospital, Seoul, Korea.

Abstract

Background: The duration of antiplatelet therapy in patients with lower extremity artery disease (LEAD) has not been well established. This study aimed to evaluate the clinical outcome according to the duration of dual-antiplatelet therapy (DAPT).
 
Methods: From April 2009 through June 2019, 376 patients with LEAD underwent successful endovascular revascularization. After the procedure, the received single-antiplatelet therapy (SAPT) or DAPT of various durations were classified into 2 groups (SAPT or DAPT < 6 months vs DAPT ≥ 6 months). The primary outcomes were major adverse cardiovascular events (MACE) and major adverse limb events (MALE). The safety outcome was moderate-to-severe bleeding according to the Global Use of Strategies to Open Occluded Arteries (GUSTO) criteria.
 
Results: Over the 40-month follow-up period, MACE occurred less frequently in the DAPT ≥ 6-month group than in the SAPT or DAPT < 6-month group (12.4% vs 23.8%; hazard ratio [HR], 0.56; 95% confidence interval [CI], 0.35 to 0.89; P = 0.014) after inverse probability-weighted adjustment and propensity-score matching analysis (HR, 0.55, 95% CI, 0.30 to 0.99, P = 0.048). MALE showed no significant differences between the 2 groups (DAPT ≥ 6-month group: 17.1% vs SAPT or DAPT < 6-month group: 13.1%; HR, 1.05; 95% CI, 0.62 to 1.78; P = 0.846). A significant difference between the DAPT ≥ 6-month group and the SAPT or DAPT < 6-month group was not observed regarding the incidence of moderate-to-severe GUSTO bleeding.
 
Conclusions: In patients with LEAD, DAPT for ≥ 6 months after endovascular revascularization was associated with a lower incidence of MACE. (Iranian Heart Journal 2024; 25(1): 42-55)

Keywords


  1. Bevan GH, White Solaru KT. Evidence-Based Medical Management of Peripheral Artery Disease. Arterioscler Thromb Vasc Biol. 2020; 40(3):541-53.
  2. Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ Res. 2015; 116(9):1509-26.
  3. Fowkes FG, Aboyans V, Fowkes FJ, McDermott MM, Sampson UK, Criqui MH. Peripheral artery disease: epidemiology and global perspectives. Nat Rev Cardiol. 2017; 14(3):156-70.
  4. Secemsky EA, Yeh RW, Kereiakes DJ, Cutlip DE, Steg PG, Massaro JM, et al. Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study. JACC Cardiovasc Interv. 2017; 10(9):942-54.
  5. Sartipy F, Sigvant B, Lundin F, Wahlberg E. Ten Year Mortality in Different Peripheral Arterial Disease Stages: A Population Based Observational Study on Outcome. Eur J Vasc Endovasc Surg. 2018; 55(4):529-36.
  6. Aboyans V, Ricco JB, Bartelink MEL, Bjorck M, Brodmann M, Cohnert T, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018; 39(9):763-816.
  7. Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017; 135(12):e726-e79.
  8. Kim TI, Chen JF, Orion KC. Practice patterns of dual antiplatelet therapy after lower extremity endovascular interventions. Vasc Med. 2019; 24(6):528-35.
  9. Soden PA, Zettervall SL, Ultee KH, Landon BE, O'Malley AJ, Goodney PP, et al. Dual antiplatelet therapy is associated with prolonged survival after lower extremity revascularization. J Vasc Surg. 2016; 64(6):1633-44 e1.
  10. Cho S, Lee YJ, Ko YG, Kang TS, Lim SH, Hong SJ, et al. Optimal Strategy for Antiplatelet Therapy After Endovascular Revascularization for Lower Extremity Peripheral Artery Disease. JACC Cardiovasc Interv. 2019; 12(23):2359-70.
  11. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007; 45 Suppl S:S5-67.
  12. Patel MR, Conte MS, Cutlip DE, Dib N, Geraghty P, Gray W, et al. Evaluation and treatment of patients with lower extremity peripheral artery disease: consensus definitions from Peripheral Academic Research Consortium (PARC). J Am Coll Cardiol. 2015; 65(9):931-41.
  13. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction: the GUSTO investigators. N Engl J Med. 1993; 329(10):673-682.
  14. Parmar GM, Novak Z, Spangler E, Patterson M, Passman MA, Beck AW, et al. Statin use improves limb salvage after intervention for peripheral arterial disease. J Vasc Surg. 2019; 70(2):539-46.
  15. Cacoub PP, Bhatt DL, Steg PG, Topol EJ, Creager MA, Investigators C. Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J. 2009; 30(2):192-201.
  16. Tepe G, Bantleon R, Brechtel K, Schmehl J, Zeller T, Claussen CD, et al. Management of peripheral arterial interventions with mono or dual antiplatelet therapy--the MIRROR study: a randomised and double-blinded clinical trial. Eur Radiol. 2012; 22(9):1998-2006.
  17. Wirtz VJ, Kaplan WA, Kwan GF, Laing RO. Access to Medications for Cardiovascular Diseases in Low- and Middle-Income Countries. Circulation. 2016; 133(21):2076-85.
  18. Valgimigli M, Gragnano F, Branca M, Franzone A, Baber U, Jang Y, et al. P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials. BMJ. 2021; 373:n1332.
  19. Spirito A, Gragnano F, Corpataux N, Vaisnora L, Galea R, Svab S, et al. Sex-Based Differences in Bleeding Risk After Percutaneous Coronary Intervention and Implications for the Academic Research Consortium High Bleeding Risk Criteria. J Am Heart Assoc. 2021; 10(12):e021965.
  20. Cesaro A, Taglialatela V, Gragnano F, Moscarella E, Fimiani F, Conte M, et al. Low-Dose Ticagrelor in Patients With High Ischemic Risk and Previous Myocardial Infarction: A Multicenter Prospective Real-World Observational Study. J Cardiovasc Pharmacol. 2020; 76(2):173-80.